

Patent Application No. 10/781,263
Atty. Dkt. No. 087147-0494

REMARKS

Applicant respectfully requests entry and reconsideration of the present application.

I. Specification

The specification is amended to correct inadvertent typographical and clerical errors in the as-filed specification.

Applicants respectfully submit that the following three terms are obvious errors whose solutions are equally obvious:

[methrazone] metolazone

[terodiline] terolidine

[valnidipine] barnidipine

No new matter has been added.

II. Disposition of the claims

Claims 1-10 are pending. Claims 11-18 were previously canceled without prejudice or disclaimer.

Claims 5, 6, 9 and 10 are amended to correct inadvertent typographical and clerical errors in the previously allowed claims. See the Appendix, which is considered part of the amendment. The Appendix shows the version of the claims with markings to show the changes made. In addition, the appendix contains pinpoint citations to the column and line number of the part of the specification that supports the amendments. No new matter is added.

III. General comments

No response was due with the RCE. A petition to withdraw from issuance under Rule 313(c) was filed with the RCE.

Patent Application No. 10/781,263
Atty. Dkt. No. 087147-0494

Conclusion

If, by the time the Examiner takes action in this application, a Supplemental Declaration for Reissue under Rule 175(b) is not in the record, the Examiner is asked to contact the undersigned, who will follow up on the matter. Otherwise, Applicants believe that the present application is in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

It is believed that the present reissue application remains in condition for allowance. Favorable consideration of the application as amended is respectfully requested. The Examiner is invited to contact the undersigned by telephone if she feels that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application, or credit any overpayment, to Deposit Account No. 19-0741.

Respectfully submitted,

Date

03-09-2007

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By

SEAN A. PASSINO (45,943) For
Stephen B. Macbius
Attorney for Applicant
Registration No. 35,264

Patent Application No. 10/781,263
Atty. Dkt. No. 087147-0494

Appendix

The following listing of the claims is a version with Markings To Show Changes Made in the traditional but superseded way. The citation in the following brackets {citation} corresponds to the pinpoint citation where support for the amendment may be found. To facilitate the Examiner's review, column 10 of the present specification is accurately reproduced below.

As compounds having diuretic activity, while mention is
30 made of amiloride, chlorothiazide, hydrochloride, benzthiazide, ticrynafen, acetazolamide, aminophylline, cyclothiazide, trichloromethiazide, cyclopenthiiazide, hydrochlorothiazide, methyclothiazide, benzylhydrochlorothiazide, penfluthiazide, ethiazide,
35 hydroflumethiazide, polythiazide, clofenamide, chlorthalidone, cyclothiazide, bendroflumethiazide, meticrane, tripamide, mettrazone, indapamide, quinethazone, furosemide, bumetanide, mefruside, azosemide, ethacrynic acid, sodium ethacrynate, piretanide,
40 spironolactone, potassium canrenoate and triamterene, mention is also made of a mixture of them or a combination of them.

As compounds having calcium antagonistic activity, while mention is made of diltiazem hydrochloride, terodiline
45 hydrochloride, nicardipine hydrochloride, valmidipine hydrochloride, flunarizim hydrochloride, verapamil hydrochloride, manidipine hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, gildipine, nimodipine, penidipine and benidipine; mention
50 is also made of a mixture of them or a combination of them.

5. (Amended) The composition of claim 4, in which the compound having diuretic activity is a member selected from the group consisting of amiloride, chlorothiazide, [hydrochloride,] {N/A} benzthiazide, ticrynafen, acetazolamide, aminophylline, cyclothiazide, [cyclopentiazide] cyclopenthiiazide {col. 10, line 32}, methyclothiazide, [benthyhydrochlorothiazide] benzylhydrochlorothiazide {col. 10, line 34}, penfluthiazide, ethiazide, hydroflumethiazide, polythiazide, [chlophenamide] clofenamide {col. 10, line 35}, chlorthalidone, cyclothiazide, bendroflumethiazide, meticrane, tripamide, [mettrazone] metolazone {col. 10, as amended herein to correct obvious error}, quinethazone, bumetanide, mefruside, azosemide, ethacrynic acid, sodium ethacrynate, piretanide, spironolactone, potassium canrenoate [, quinethazone] {N/A} and triamterene.

Patent Application No. 10/781,263
Atty. Dkt. No. 087147-0494

6. (Amended) The composition of claim 4, in which the compound having calcium antagonistic activity is a member selected from the group consisting of diltiazem hydrochloride, [teloridine] terolidine hydrochloride {col. 10, as amended herein to correct obvious error}, nicardipine hydrochloride, [varnidipine] barnidipine hydrochloride {col. 10, as amended herein to correct obvious error}, flunarizine hydrochloride, verapamil hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, nildipine, nimodipine, penidipine and benidipine.

9. (Amended) The method of claim 7, wherein the compound having diuretic activity is a member selected from the group consisting of amiloride, chlorothiazide, [hydrochloride,] benzthiazide, ticrynafen, acetazolamide, aminophylline, cyclothiazide, trichloromethiazide, [cyclopentiazide] cyclopenthiazide {col. 10, line 32}, hydrochlorothiazide, methyclothiazide, [benthylhydrochlorothiazide] benzylhydrochlorothiazide {col. 10, line 34}, penfluthiazide, ethiazide, hydroflumethiazide, polythiazide, [chlophenamide] clofenamide {col. 10, line 35}, chlorthalidone, cyclothiazide, bendroflumethiazide, meticrane, tripamide, [metrazone] metolazone {col. 10, as amended herein to correct obvious error}, indapamide, quinethazone, furosemide, bumetanide, mefruside, azosemide, ethacrynic acid, sodium ethacrylate, piretanide, spironolactone, potassium canrenoate [, quinethazone] { N/A} and triamterene.

10. (Amended) The method of claim 7, wherein the compound having calcium antagonistic activity is a member selected from the group consisting of diltiazem hydrochloride, [teloridine] terolidine hydrochloride {col. 10, as amended herein to correct obvious error}, nicardipine hydrochloride, [varnidipine] barnidipine hydrochloride {col. 10, as amended herein to correct obvious error}, flunarizine hydrochloride, verapamil hydrochloride, manidipine hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, nildipine, nimodipine, penidipine and benidipine.